Health

By Dan Cimaglia

Health - To lockdown or not to lockdown

#24・ May 11, 2020

5.83K

subscribers

issues

Issue #24 — View online — Suggest a link

Health

The latest news and information about innovations in healthcare!

Hi folks!

I am a huge fan of Elon Musk. I first heard about him when I was 19 years old, at the very beginning of my medical studies. I think I spent more than 100 hours in total to read and watch about his life that year. His story is definitely inspiring. He is hope.

But hope can sometimes disappoint. So has Elon. Like when he started tweeting against lockdown, which is the only way to protect our elderlies from this very viral virus, for the benefit of Tesla’s stock, putting hundreds of lives at risk.

As the articles we curated this week show, until scientists find a vaccine, we’ll really need to act very cautiously.

Please take care of you and your relatives,

-Alaedine

What about science?

Each week, we curate some scientific articles that introduce a disrupting innovation or a worth-reading opinion.

Leveraging Advances in Artificial Intelligence to Improve the Quality and Timing of Palliative Care | Cancers

One of the fields that has not been the focus of AI and therefore has been largely unaffected by the recent advances is palliative care is palliative care, a discipline of increasing importance in the aging population of the industrialized nations.

Read now | Share

Generation and evaluation of synthetic patient data | BMC

AI impact in medicine has been undeniably slower and more limited than in other application domains. A major reason for this has been the lack of availability of patient data. High-quality, realistic, synthetic datasets can be leveraged to accelerate methodological developments in medicine.

Read now | Share

Wearable Devices for Ambulatory Cardiac Monitoring: JACC State-of-the-Art Review

Ambulatory monitoring devices are enabling a new paradigm of health care by collecting and analyzing long-term data for reliable diagnostics.

Read now | Share

Week's hot trends and impacts

Thoughts on testing, tracking apps and the lockdown. Bonus: a really funny article from Nature.

First CRISPR test for the coronavirus approved in the United States | Nature

The kit has been granted approval under ‘emergency use’ provisions, and should help to ease testing backlogs in the country.

Read now | Share

A flood of coronavirus apps are tracking us. Now it’s time to keep track of them. | MIT Technology Review

There's a deluge of apps that detect your covid-19 exposure, often with little transparency. Our Covid Tracing Tracker project will document them.

Read now | Share

When Will It Be Safe to End Coronavirus Lockdowns? | The New Yorker

The lead author of a new study on why opening now could be a mistake, and why the lack of federal leadership will make it more difficult to identify long-term solutions.

Read now | Share

Coronavirus diaries: All the things we do not do | Nature

Lockdowns offer a break from failed experiments, laboratory admin duties, airport check-ins and wearing shoes, says John Tregoning.

Read now | Share

For VCs

Some of the biggest fundraising/acquisition of the week.

LetsGetChecked Nabs $71M for Direct-to-Consumer At-Home Health Testing

At-home health testing company LetsGetChecked announced a $71M funding round led by Illumina Ventures and HLM Ventures Partners.

Read now | Share

Medable Secures $25M Funding To Reduce Clinical Trial Timelines

Palo Alto, California startup Medable Inc. raised $25 million in funding led by GSR Ventures, to accelerate clinical drug development with digital technology.

Read now | Share

Owkin raises $25 million as it builds a secure network for healthcare analysis and research

Owkin has raised $25 million in fresh financing from investors, including Bpifrance Large Venture, Cathay Innovation and MACSF (the French Pension Fund for Clinicians), alongside previous investors GV, F-Prime Capital and Eight Roads.

Read now | Share

Book of the week

Too Smart | The MIT Press

Who benefits from smart technology? Whose interests are served when we trade our personal data for convenience and connectivity?

In Too Smart, Jathan Sadowski looks at the proliferation of smart stuff in our lives and asks whether the tradeoff—exchanging our personal data for convenience and connectivity—is worth it.

Read now | Share

Techstars Startup Digest Health is curated by:

Dan Cimaglia
dan.cimaglia@startupdigestmail.com

Did you enjoy this issue?

Did you see something you think we should include in our newsletter? Suggest a link.

If you were forwarded this newsletter and you like it, you can subscribe here.

If you don’t want to receive this newsletter anymore, unsubscribe here.